COVID-19 impacts cancer diagnosis
The healthcare community’s understanding of the impact of the COVID-19 pandemic on routine patient care continues to grow. A recent study by Quest Diagnostics published by JAMA Network Open found a 46% drop in detection of all cancers during a 7-week period in March and April 2020.1
Colorectal cancer and breast cancer saw an even bigger drop of more than 49% and 52% respectively.1 Click here for our overview of the findings.
We are partnering with Walmart® Neighborhood Markets throughout the US to make COVID-19 molecular testing available through the pharmacy drive-thru, making it easy to ensure that patients are screened for active COVID-19 infection prior to office visits and surgeries.
Our Back to Care program offers helpful models to support both healthy and immunocompromised patients get the necessary testing they need for any deferred care.
Solutions for cancer testing
Quest offers a comprehensive cancer testing menu:
Stay in touch
To stay up-to-date with the latest information from Quest Diagnostics, please fill out the form below.
* Required fields
Reference:
- Kaufman HW, Chen Z, Niles J, Fesko Y. Changes in the number of US patients with newly identified cancer before and during the coronavirus disease 2019 (COVID-19) pandemic. JAMA Netw Open. 2020;3(8):e2017267. doi:10.1001/jamanetworkopen.2020.17267